This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

A Survey of Midazolam in People With Status Epilepticus

Sponsored by Takeda

About this trial

Last updated 2 years ago

Study ID

TAK-815-5001

Status

Recruiting

Type

Observational

Placebo

No

Accepting

All Ages
All Sexes

Not accepting

Healthy Volunteers

Trial Timing

Started 5 years ago

What is this trial about?

This study is a survey in Japan of midazolam oromucosal solution used to treat people with status epilepticus. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from midazolam oromucosal solution and to check if midazolam oromucosal solution improves symptoms of status epilepticus. During the study, participants with status epilepticus will take midazolam oromucosal solution according to their clinic's standard practice. The study doctors will check for side effects from midazolam for 6 months.

What are the participation requirements?

Inclusion Criteria

Must be with nonconvulsive status epilepticus.

Exclusion Criteria

Cannot have a history of hypersensitivity to any component of midazolam.

Study Document Downloads

Subscribe and get notified when study documents are available.

For more information, view the full study details:

NCT05313308      jRCT2031210712